Navigation Links
How embryonic stem cells develop into tissue-specific cells demonstrated
Date:5/12/2008

Jerusalem, May 12, 2008 While it has long been known that embryonic stem cells have the ability to develop into any kind of tissue-specific cells, the exact mechanism as to how this occurs has heretofore not been demonstrated. Now, researchers at the Hebrew University of Jerusalem and elsewhere have succeeded in graphically revealing this process, resolving a long-standing question as to whether the stem cells achieve their development through selective activation or selective repression of genes.

The collaborative research group, which included Dr. Eran Meshorer of the Department of Genetics at the Silberman Institute of Life Sciences at the Hebrew University of Jerusalem, has revealed that the embryonic stem (ES) cells express large proportions of their genome promiscuously. This permissive expression includes lineage-specific and tissue-specific genes, non-coding regions of the genome that are normally silent, and repetitive sequences in the genome, which comprise the majority of the mammalian genome but are also normally not expressed.

When ES cells differentiate into specific cell tissue-types, they undergo global genetic silencing. But until this occurs, the ES cells maintain an open and active genome. This might very well be the secret of their success, since by maintaining this flexibility they maintain their capacity to become any cell type. Once silencing, or genetic repression, occurs, this ability is gone.

Thus, one can say that the ES cells stand at the ready until the last minute -- prepared to engage in selective activation into specific cells -- holding in abeyance their ability to become any kind of cells at the point and time required.

To reveal the process as to how this occurs, the researchers created the first full-mouse genomic platform of DNA microarrays. Microarrays are glass-based chips that allow simultaneous detection of thousands of genes. The microarrays used in the study were not confined t
'/>"/>

Contact: Jerry Barach
jerryb@savion.huji.ac.il
972-258-82904
The Hebrew University of Jerusalem
Source:Eurekalert

Page: 1 2

Related medicine news :

1. March of Dimes awards $250,000 prize to leaders in understanding embryonic development
2. Mouse Skin Cells Reprogrammed to Act Like Embryonic Stem Cells
3. Embryonic Stem Cells Turned Into Three Types of Heart Cells
4. Embryonic stem cells could help to overcome immune rejection problems
5. Module map links embryonic stem cells and cancer stem cells
6. UCLA researchers examine human embryonic stem cell genome
7. Protein in Human Embryonic Stem Cells Controls Malignant Tumor Cells
8. Molecular alliance that sustains embryonic stem cell state
9. Embryonic Stem Cell Protein Inhibits Melanoma
10. Protein in embryonic stem cells control malignant tumor cells
11. Rutgers researchers unlock mysteries of vitamin A metabolism during embryonic development

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)... Linemen especially likely to have metabolic syndr...HealthDay News) -- Exercise alone isn,t enough to ...g at higher risk for a medical condition that can ...Researchers studied linemen at Division I colleges...2 percent had metabolic syndrome, a group of condi...
(Date:12/2/2009)..., , VIRGINIA BEACH, Va., Dec. 2 /PRNewsw...garette. These smokeless cigarettes continue to gr...arket is now available at the PremiumEcigarette - ...ctronic cigarette - at the amazingly low price of ...for people to try the e-cigarette at a very low pr...
(Date:12/2/2009)..., , MONTREAL, Dec. 2 /PRNewswire/ - As pa...around the world, Wyeth, now a part of Pfizer, has...(IUs) of factor concentrates to the World Federati...on ever made to the WFH,s Humanitarian Aid Program...e WFH,s goals. ,, "This donation will directly ...
(Date:12/2/2009)..., , KNOXVILLE, Tenn., Dec. 2 /PRNewswire... presence in Southwest Florida with the acquisitio...LLC (EPN). Since January 2002, EPN has held an ex...ff the emergency facilities at the Downtown Naples...althcare Clinic. EPN also provides the staffing fo...
(Date:12/2/2009)..., EUROECHO 2009 is the official congress of the E...egistered branch of the European Society of Cardio...imaging will be presented. , New case reports w... latest evidence highlighting the role of this new... in imaging techniques, it is likely that non-inva...
Breaking Medicine News(10 mins):Health News:Oversized College Football Players May Face Heart Risks 2Health News:A Smokeless Holiday Season? Premium Electronic Cigarette Announces New Disposable Smokeless Cigarette Product 2Health News:The WFH receives the largest humanitarian aid donation in its history - Donation represents more than 40 million international units to the WFH 2Health News:TeamHealth Acquires Emergency Physicians of Naples, LLC 2Health News:Media alert: EUROECHO 2009 2
... regimen combining vinorelbine (Navelbine) and mit...rednisone is effective in the treatment of hormone... treatment should be offered to symptomatic patien...nts who had advanced prostate cancer, the investig...
...ion caused by the heart's inability to pump effici... and weaker. An estimated 5 million Americans ha...hin five years. It can be caused by high blood pre...ducing inflammation, helping to better control the...
...er whether hormone replacement therapy is safe and...tudy examines the pros and cons of this controvers... combined HRT therapy for five years. All the wome...uld not use HRT therapy because of the associated ...
...women more severely than men and greatly impacts t...University of Massachusetts Medical School, analyz...attention for chronic cough and a control group of... chronic cough group reported physical and extreme...
...nges from 10 percent to 25 percent, with the peak ...ars. Some reports suggest as many as 14 percent of...5 percent of women use antidepressants during preg... for pregnant women. However, most of these studie...
...ing a soft plastic tube or catheter into the linin...st undergo training for two weeks and are then abl...m the comfort of their home. Hemodialysis patients... kidney disease would choose home-based peritoneal...
Other Medicine News:Health News:A Combination Of Drugs Effective In The Treatment Of Hormone-Refractory Prostate Cancer 2
(Date:12/2/2009)... , PLEASANTON, Calif., Dec. 2 /PRNewswire-Firs...nced today that the United States Food & Drug ...ed use for its licensed nucleic acid test, to scre...dividual donations. The test, called the cobas... system, is a qualitative, in-vitro test for the s...
(Date:12/2/2009)... , NANJING, China, Dec. 2 /PRNewswire-...r the "Company") (NYSE: SCR ), a leading pharmac...anufacturing, and marketing of branded,generic and...ted that its,subsidiary Jiangsu Yanshen Biological...s suspended production of all its products in orde...
(Date:12/2/2009)... , EAST HANOVER, N.J., Dec. 2 /PRNewsw...cluding a late-breaking presentation on Tasigna...ic myeloid leukemia, demonstrate the strength of t... care of patients. ,, The new data, at the 51s...ing and Exposition, highlight the company,s curren...
Breaking Medicine Technology:FDA Approves Use of Roche Test to Screen Source Plasma for HIV, Hepatitis B Virus and Hepatitis C Virus 2FDA Approves Use of Roche Test to Screen Source Plasma for HIV, Hepatitis B Virus and Hepatitis C Virus 3Simcere Pharmaceutical Group Announces Jiangsu Yanshen's Voluntary Suspension of Production 2Simcere Pharmaceutical Group Announces Jiangsu Yanshen's Voluntary Suspension of Production 3Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 2Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 3Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 4Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 5Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 7Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 8Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 9Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 10Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 11Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 12Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 13Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 14Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 15Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 16Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 17Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 18Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 19Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 20Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 21Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 22Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 23Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 24Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 25Brain computer interface developed at Brown begins new clinical trial 8783 1Brain computer interface developed at Brown begins new clinical trial 8783 2Brain computer interface developed at Brown begins new clinical trial 8783 3Brain computer interface developed at Brown begins new clinical trial 8783 4Published Study Shows VNUS ClosureFAST 26amp 3B 238482 3B System Significantly Superior to Laser for Varicose Vein Treatment 48411 1Published Study Shows VNUS ClosureFAST 26amp 3B 238482 3B System Significantly Superior to Laser for Varicose Vein Treatment 48411 2Published Study Shows VNUS ClosureFAST 26amp 3B 238482 3B System Significantly Superior to Laser for Varicose Vein Treatment 48411 3Forterus Inc Announces Special Board Meeting 3B Nominates Jeff Walton Former Bear Stearns President to Board of Directors 48408 1Forterus Inc Announces Special Board Meeting 3B Nominates Jeff Walton Former Bear Stearns President to Board of Directors 48408 2
...nces announced,today, the initiation of a Phase 2 ...he treatment and management of acute infectious,mo...apeutics for the,treatment for this debilitating c...n-Barr virus (EBV), "Valomaciclovir has shown a b...ibition of viral replication of herpes zoster and ...
...gel,Pharmaceuticals, Inc. (Nasdaq: RIGL ) today a... PFE ), has begun a Phase 1 clinical trial of an,...kinase inhibitor, R343,for the treatment of allerg...Rigel,s clinical portfolio., Under the terms of t...will receive a $5 million milestone payment from P...
Other Medicine Technology:Epiphany Biosciences Reports Initiation of Phase 2 Study of Valomaciclovir for the Treatment of Acute Infectious Mononucleosis 2Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer 2Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer 3
Alloclassic Hip
Perfecta RS Stems
S-ROM Femoral Stems - XX-Long Length Stems 36mm Neck with 21mm Calcar Replacement + Lat Neck
S-ROM Femoral Stems - Long Length Stems Standard 36mm Neck
Medicine Products: